AMAN · Amanat Acquisition Corp Class A Ordinary Shares

Amanat Acquisition Corp represents a healthcare-focused SPAC led by experienced biotech executives targeting clinical/pre-commercial companies in a market where robust VC funding ($26B in 2024) meets selective IPO conditions, creating opportunities for de-SPAC transactions. The $75M IPO (upsizable to $86.25M) places 100% of proceeds in trust at $10/share, with no warrants issued—reducing typical SPAC dilution—and sponsor committing $3M in private shares. Founder shares (20% ownership) bought at $0.012/share create immediate 103%+ dilution to public holders upon conversion, exacerbated by anti-dilution protections ensuring sponsor maintains ~20% post-merger even with additional issuances. Management's track record shines: Kulkarni drove Zura Bio's de-SPAC and Tourmaline's $1.4B Novartis sale; Cheruvu raised $300M+ across biotechs; Fernandez brings SPAC CFO/directorship experience. This positions Amanat to source proprietary deals via networks spanning academia, Big Pharma, and crossover financings, targeting undervalued assets with clinical data and IP moats amid $5.3T U.S. healthcare spend projected to 20% GDP by 2033.

Financially pre-operational with $19k loss since inception, post-IPO ~$1.5M working capital supports 24-month search, but high redemptions (up to 100%, capped at 20% per group without consent) pose completion risk—especially for cash-intensive biotech targets. Proceeds fund one sizable deal (80% fair value test), likely requiring PIPEs for larger enterprises. Governance includes independent audit committee (financial expert), staggered board potential, and Cayman incorporation with tax exemption to 2056. Conflicts loom: management's other SPAC/biotech roles, corporate opportunity waiver allowing parallel pursuits, and sponsor incentives favoring any deal over none. CFIUS risks noted for U.S.-sensitive targets. Investors face binary biotech outcomes (7.9-14.3% Phase 1-to-approval odds) but benefit from team's $20B+ value creation history. Post-merger, expect active stewardship with board continuity.